Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Bullboard Posts
Comment by superfido10on Jun 04, 2020 11:04pm
226 Views
Post# 31114700

RE:Mmmmm beer

RE:Mmmmm beer Nice Post Baystreet Staff - Thursday, June 4, 2020 Psilocybin: The Weight Loss Secret Weve Been Searching For? The global obesity epidemic has been bursting at the seams. However, a solution may be found in psychedelics such as psilocybin, which activates serotonin receptors, or natures own appetite suppressant, as noted by Psychology Today. This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight. If this is the case, we may come one step closer to stopping the global obesity epidemic that could impact nearly half of all U.S. adults by 2030. At the moment, 34% of U.S. adults and up to 20% of children are considered obese. Those successful in helping to treat the epidemic could see multi-billion-dollar market opportunity. As we learn more about how useful such treatments can be, its opening a wide range of opportunity for companies like The Yield Growth Corp. (CSE:BOSS)(OTC:BOSQF), Champignon Brands Inc. (OTC:SHRMF)(CSE:SHRM), Mind Medicine Inc. (OTC:MMEDF), Johnson & Johnson (NYSE:JNJ), and Revive Therapeutics Ltd. (CSE:RVV)(OTC:RVVTF).
Bullboard Posts